6533b7d8fe1ef96bd126ad8d

RESEARCH PRODUCT

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Massimo BarberisAlessandro RussoFrancesca CastiglioneFiamma ButtittaDaniela MedicinaUmberto MalapelleGiancarlo TronconeAntonino IaccarinoFabiana Letizia CecereStefania TommasiGiuseppe PalmieriLuisella RighiRoberta MinariGiulio RossiAntonio M. GrimaldiFabio MeleElisabetta OrlandoPasquale PisapiaWilliam VermiFabio PagniAntonio MarchettiDaniela Massi

subject

0301 basic medicineOncologyProto-Oncogene Proteins B-rafmedicine.medical_specialtyPredictive molecular pathologyLung NeoplasmsGene mutationBRAF03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansNon-Small-Cell LungVemurafenibLung cancerneoplasmsMelanomaTrametinibCobimetinibbusiness.industryBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology; Biomarkers; Humans; Mutation; Proto-Oncogene Proteins B-raf; Carcinoma Non-Small-Cell Lung; Lung Neoplasms; MelanomaCarcinomaPrecision medicineDabrafenibHematologyBiomarkerPrecision medicinemedicine.diseaseBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathologyLung Neoplasm030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMutationPersonalized medicineLung cancerbusinessBiomarkersmedicine.drugHuman

description

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

yearjournalcountryeditionlanguage
2020-01-01
10.1016/j.critrevonc.2020.103118http://hdl.handle.net/11588/828180